Document is current

Article History

Received: 15 November 2021

Accepted: 21 January 2022

First Online: 4 March 2022

Declarations

:

: This project was approved by the INSERM CEEI/IRB ethics committee (Avis n°20–664). PBMCs were isolated from healthy donor blood (under agreement EFS C CPSL UNT N° 20/EFS/005). Animal care and use for this study were performed in accordance with the recommendations of the European Community (2010/63/UE) for the care and use of laboratory animals. All experiments were approved by the French National Animal Care and Use Committee (CEEA 26: #2017122111548235_v2, the Gustave Roussy preclinical facility, Villejuif, France). All experiments were approved by the French National Animal Care and Use Committee (APAFlS# 6725–2016091415495765-v8, CRCT Toulouse France). The use of tissue samples has been approved by our institutional ethics committee (patient collection samples: DC-2020-4074; AC-2020-4031 (CRB of CHU Toulouse)).

: Not applicable.

: The following authors (EB, TM, LB, ER, AD, FM and LL) declare a European patent application for “Methods For The Treatment Of Anaplastic Large Cell Lymphoma” (reference: BRUNET21072MC/ BTL, April 9, 2021, application number EP21305467, applicants INSERM, and IMAGINE Institute, France).